{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017140","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.004268+00:00","generated_at":"2026-06-22T00:45:16.484850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros reports Q3 2022 net loss $17.5M; FDA denies narsoplimab appeal, provides resubmission path","bullets":["Net loss $17.5M ($0.28/share) vs $22.7M loss in 3Q21; cash and equivalents $221M at Sept 30.","FDA denied Formal Dispute Resolution for narsoplimab BLA; proposes resubmission with survival vs historical control.","Sold interest in OMIDRIA royalties to DRI for $125M cash; max DRI payout $188.4M at 9.4% effective rate.","CMS final rule confirms separate OMIDRIA payment in ambulatory surgical centers for 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017140","json":"https://secwatch.observer/filing/0001558370-22-017140.json","markdown":"https://secwatch.observer/filing/0001558370-22-017140.md","text":"https://secwatch.observer/filing/0001558370-22-017140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022017140/0001558370-22-017140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022017140/omer-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:45:16.484850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f2e957d8e2f4889ac695fee755c8f18aee7c0b5","claim":"OMEROS CORP reported financial results for three and nine months ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022017140/0001558370-22-017140-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}